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Abstract
Purpose The purpose of the article is to present standard set of outcomes for people with personality disorder (PD), in order 
to facilitate patient outcome measurement worldwide.
Methods The International Consortium for Health Outcomes Measurement (ICHOM) gathered a multidisciplinary inter-
national working group, consisting of 16 experts, including clinicians, nurses, psychologists, methodologists and patient 
representatives, to develop a standard set of outcome measures for people with PD. The Delphi method was used to reach 
consensus on the scope of the set, outcome domains, outcome measures, case-mix variables and time points for measuring 
outcomes in service users. For each phase, a project team prepared materials based on systematic literature reviews and 
consultations with experts.
Results The working group decided to include PD, as defined by International Classification of Diseases 11th revision (ICD-
11). Eleven core outcomes and three optional outcomes across four health domains (mental health, behaviour, functioning 
and recovery) were defined as those relevant for people with PD. Validated measures for the selected outcomes were selected, 
some covering more than one outcome. Case-mix variables were aligned to other ICHOM mental health standard sets and 
consisted of demographic factors and those related to the treatment that people received. The group recommended that most 
outcomes are measured at baseline and annually.
Conclusion The international minimum standard set of outcomes has the potential to improve clinical decision making 
through systematic measurement and comparability. This will be key in improving the standard of health care for people 
with PD across the world.
Keywords ICHOM · Patient-reported outcomes · Personality disorder · Quality of life · Risk-adjustment variables · Delphi 
procedure
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Introduction
People with personality disorder (PD) have problems in 
functioning of aspects of self and interpersonal dysfunction 
which lead to emotional distress and impaired social func-
tion [1]. With onset early in life [2], high prevalence of over 
5% of the general population and 50% in the outpatient psy-
chiatric settings [3], it contributes to a substantial portion of 
health-care spending [4]. Most of the costs are incurred by 
inpatient and community mental health care and increased 
levels of unemployment and lost productivity among peo-
ple with PD. A variety of psychological and psychosocial 
interventions have been shown to improve the mental health 
of people with PD [5–7]. The wide consensus is that the 
primary treatment for PD should be outpatient psychosocial 
therapy, with pharmacological treatment used mainly for the 
treatment of coexisting conditions. Further recommendation 
regarding the length and modality of treatments for each 
trait profile of PD is not clear, differs among countries and 
are often not in line with the latest research [8]. Compared 
to other common mental disorders, personality pathology is 
rarely tracked in routine clinical care. While many settings 
routinely assess the outcomes of people with depression and 
anxiety [9], outcome assessment in PD is rare and mostly 
refers to borderline personality disorders (BPD). In BPD, 
meta-analyses and reviews highlight the variety of outcomes 
utilized. Stoffers et al. [10] defined primary outcomes, which 
included overall BPD severity and BPD symptoms severity; 
and secondary outcomes, which included psychiatric comor-
bidity, general distress, global assessment of functioning, 
attrition/noncompliance with treatment, and adverse events. 
Lieb et al. [11] used all the outcomes from Stoffers et al. 
but added hospitalizations, emergency department visits, 
medication tolerability and side effects. Further outcomes 
measured in longer-term studies are social and vocational 
functioning, symptomatic remission and recovery from BPD 
[12].
In order to establish the value of each treatment for each 
service user, monitoring of health outcomes is essential. 
Value of treatment is defined as ‘the outcomes achieved 
relative to the costs’ [13]. For multiple reasons, measuring 
outcomes in the mental health is less common and more 
difficult than elsewhere, in spite of many available and vali-
dated health outcomes measures [14]. First of all, measure-
ment precision of instruments might be lower compared to 
biomarkers. In addition, many instruments are time consum-
ing, and clinicians might lack resources to implement them 
in busy clinical settings [14]. Also, there are many outcome 
measures available to measure each domain or symptom, 
making the results difficult to compare.
ICHOM was established to review the existing out-
come measures that matter most to patients and to outline 
minimum standard sets of outcomes, measurement instru-
ments, timepoints and risk adjustment factors for various 
conditions [15]. In 2018, ICHOM set out to cover some of 
the most prevalent mental health conditions. An interna-
tional, multidisciplinary working group, led by ICHOM, 
was set up in the end of 2018. Our aim was to define the 
outcomes that matter most to persons with PD and pre-




The development of standard set for PD was initiated by 
ICHOM, which sets up a small project team (M.C., L.S.F., 
B.J., L.-M. C, T.G and V.P.R) and a wider working group. 
The wider working group consisted of 16 experts, includ-
ing clinicians, nurses, patient representatives and experts in 
the area of outcome measurement. Working Group selection 
criteria defined by ICHOM were strictly followed; the mem-
bers of the Working Group committed to active engagement 
and participation and were selected to cover the breadth of 
expertise needed to develop the content of the standard 
set—clinical expertise, PROMs expertise and health-care 
system evaluation expertise. The working group members 
came from Europe, North America, Latin America, Middle 
East, Australia and New Zealand, representing all regions 
of the world. Their work was coordinated and guided by the 
project team.
Work process and decision making
The working group convened via eight video calls from 
March 2019 to March 2020. Their work followed the Delphi 
process, previously modified and applied by ICHOM in the 
course of preparation of standard sets for a number of con-
ditions [16–21]. A standard set of outcomes was developed 
through several phases (Fig. 1). Each teleconference had a 
previously determined goal, which was defined according 
to the issues that arose in the process of the development 
of the standard set. In line with the set goal, the project 
team prepared the research inputs based on the reviews of 
literature using common databases (PubMed, EMBASE, 
CINAHL, Medline, PsycINFO) and reviews of treatment 
guidelines and registries (e.g. Personality Disorders Regis-
try Spain; Guideline on BPD: recognition and management, 
England; Guideline on Antisocial Personality Disorder: pre-
vention and management, England; Guideline on Antiso-
cial behaviour and conduct disorders in children and young 
persons: recognition and management, England; Guideline 
on Personality Disorders, Germany; National Outcomes 
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Fig. 1  Process of the outcomes development
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and Case-mix Collection (NOCC), Australia; APA’s Mental 
health registry PsychPRO, USA; Mental Health Registry). 
Additionally, breakout groups were set up to discuss most 
relevant issues to decrease the complexity of the issues to 
be decided on at the working group calls.
Breakout groups were organized to discuss the issues of 
instrument selection and packages as well as to harmonize 
standard sets regarding outcome instruments, timepoints and 
case-mix variables across mental health working groups. 
At the teleconferences, gathered and analysed information, 
including proposals, was presented for group discussion. 
After each teleconference, the discussed content was organ-
ized into an online survey. It was emailed to working group 
members who were invited to vote on the issues discussed.
Content was included if 70% consensus was reached and 
excluded if less than 50% consensus was reached. Issues that 
remained inconclusive were further discussed and subjected 
to additional rounds of voting until a consensus was reached, 
following the rules from the previous sentence. At least an 
80% of the group had to take part in a vote for it to be con-
sidered valid. A consensus had to be reached in four major 
decision areas: (1) scope: which conditions, population age 
and treatments should be included in the PD standard set, (2) 
outcome domains and outcomes in each domain, (3) instru-
ments and instrument packages in each of the domains and 
(4) case-mix variables and timepoints.
To vote on outcomes, working group members discussed 
the long list of potentially relevant outcomes on the call and 
then voted online anonymously after reviewing the mate-
rials and minutes from the call. This was done using an 
online survey, where they were presented with each out-
come and asked to rate the outcome on a scale from 1 to 
9 (1 = not important, 9 = essential). Inclusion in the stand-
ard set required that a minimum of 80% of the consensus 
working group voted an item as “essential” (score of 7–9) 
in the first or second round Delphi vote. When consensus 
was not reached by voting, the item was discussed and revis-
ited in the next videoconference and survey. Outcomes were 
excluded if a minimum of 80% of the consensus working 
group voted an item as “not recommended” (score 1–3). 
The consensus working group voted on all inconclusive 
outcomes in the final survey round, following ICHOM pro-
cesses, in which the response options were simply “include” 
or “exclude”. In this final round, inclusion in the standard set 
required only 70% consensus. A similar process was used to 
reach consensus on recommended measures and risk adjust-
ment factors.
Definition of scope and selection of outcome 
domains and outcomes
Preceding the launch call, a systematic literature review was 
performed in November 2018 to define the scope of the work. 
The following databases were searched: Medline and Embase 
in Ovid and CINAHL and Psychinfo in Ebsco. Out of 3270 
articles identified, 49 were included in the scope definition. 
Due to the high number of hits the decision was taken to con-
duct all further searches in Medline at first and only extend 
the search to other databases if necessary. The following sys-
tematic literature search for outcome domains was conducted 
in Medline in March 2019 (Fig. 2). Additionally, treatment 
guidelines and registries were taken into account to develop 
the final definition of outcome domains and outcomes.
Selection of outcome measures
The selection of outcome measures was based on the sys-
tematic literature review in Fig. 2. A total of 268 potentially 
relevant patient-reported outcome measures (PROMs) were 
screened with respect to (1) conceptual and measurement 
model, (2) evidence supporting psychometric properties, e.g. 
validity and reliability, (3) clinical utility, (4) feasibility of 
implementation (licensing fees – measures that need to be 
paid for were excluded, number of language translations, 
number of citations, and service user and administrative 
burden – length of the questionnaire and (5) harmonization 
with other mental health standard sets. Additional litera-
ture searches were conducted in PubMed for each measure 
undergoing screening. The measures that passed the initial 
screening by the project team of the 268 potentially relevant 
patient-reported outcome measures (PROMs) identified 
were then presented to the working group, alongside evi-
dence supporting psychometric properties, e.g. validity and 
reliability. The working group discussed the issues around 
clinical utility, psychometric properties, feasibility of imple-
mentation and benchmarking potential during the working 
group call.
Following this discussion, the working group members 
voted anonymously on an online survey about which meas-
ure should capture which outcome individually. The decision 
to include or exclude a measure required 70% consensus, 
with a minimum of 80% participation from working group 
members.
To establish cross-cultural equivalence between the vari-
ous countries, a list of case-mix variables was extracted 
from the registries and PD guidelines. Case-mix variables 
(Table 4) describe the context in which the outcomes are 
measured. To ensure high level of harmonization, previous 
ICHOM standard sets were reviewed for definition of demo-
graphic and socioeconomic variables.
External validation by health professional 
and service user experts
In February 2020, ICHOM presented a draft recommended 
PD standard set, which was sent into open review process by 
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professionals and into service user validation process. Any 
results securing an endorsement higher than 70% from the 
open review panel (service users) were accepted, while those 
receiving a lower endorsement went into further discussion 
with working group members.
Search term: (“personality disorder” [ti] OR “border-
line personality disorder”[tiab] OR “schizotypal personal-
ity disorder”[tiab] OR “schizoid personality disorder”[tiab] 
OR “histrionic personality disorder”[tiab] OR “narcissis-
tic personality disorder”[tiab] OR “paranoid personality 
disorder”[tiab] OR “avoidant personality disorder”[tiab] OR 
“antisocial personality disorder”[tiab] OR “dependent per-
sonality disorder”[tiab] OR “obsessive–compulsive person-
ality disorder”[tiab] OR “Negative affectivity in personality 
disorder or personality difficulty”[tiab] OR “Detachment in 
personality disorder or personality difficulty”[tiab] OR “Dis-
sociality in personality disorder or personality difficulty”[tiab] 
OR “Disinhibition in personality disorder or personality 
difficulty”[tiab] OR “Anankastia in personality disorder or 
personality difficulty”[tiab] OR “Borderline pattern”[tiab]) 




The working group decided to include PD as defined 
by International Classification of Diseases 11th revi-
sion (ICD-11) [1]. Substance use-induced PD, PD due to 
organic causes including head injury, personality change/
disorder secondary to other mental health condition, sub-
threshold personality dysfunction and personality diffi-
culty were excluded from the scope of the project. The 
settings included primary care, inpatient and outpatient 
care, day hospital, community treatment, forensic men-
tal health services, family care, and criminal justice care 
in a form of group as well as individual therapies. All 
psychotherapeutic and pharmacological treatments were 
voted within scope, except use of drugs for comorbid con-
ditions. Recommendations were limited to adults and ado-
lescents aged 13 years or above – for children aged 2–12 
that there is not much literature on PDs and the outcomes 
measures used are different. The literature [22] suggests 
Fig. 2  Search strategy and selection process for final inclusion of outcome domains considered for the final PD standard set
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that PD begins in childhood and adolescence, and can be 
diagnosed in young people. For example, BPD is common 
among young people: the estimated prevalence is 1–3% 
in the community, rising to 11–22% in outpatients, and 
33–49% in inpatients. BPD is one of the leading causes 
of disability-adjusted life years (DALYs) in young people 
among mental diseases and represents a substantial finan-
cial burden for the families of young people. The effective-
ness of structured treatments for BPD in young people has 
been demonstrated.
Outcome domains and measures
Based on the literature review, a list of 50 outcomes in eight 
outcome domains was proposed for voting. This list was 
later expanded and refined following the suggestions, dis-
cussion and three rounds of Delphi voting by working group 
members. The final list consists of 14 outcomes, grouped in 
four outcome domains [9]: (1) Mental health, (2) Behaviour, 
(3) Functioning and (4) Recovery. All the outcomes consid-
ered for the inclusion in the PD standard set are presented 
in Table 1.
A comprehensive literature review was performed for 
each of the outcomes in order to identify the instruments 
within the defined scope of the standard set. A total of 268 
instruments identified were screened and reduced to 13 
instruments (Table 2). A breakout group was established 
to help ensure that the measures were harmonized to the 
highest possible degree among mental health standard 
sets. As there were four mental health sets in development 
simultaneously and all of them included “Functioning” and 
“Health-Related Quality of Life", the same instruments to 
cover the same domain across the mental health sets were 
used. Members of the group also expressed a preference 
for measures that were appropriate for both adolescents 
and adults in order to enable tracking the mental health 
outcomes during this period.
As the number of the outcomes was high, measures that 
could cover more than one domain were looked for, which 
could later be complemented by additional instruments. 
Measures with positive framing of the questions were 
preferred: this decision was made by the working group 
following feedback on the content and phrasing from the 
lived experience representatives.
Due to a high degree of overlap in the domains that 
different measures covered, instrument package options 
were then prepared for voting in the final phase. The group 
aimed to ensure that the final package of measures would 
take a person less than 25 min to complete. The final 
outcomes and the measures are presented in Fig. 3 and 
Table 3. While most of the outcomes are core, “Emotional 
Dysregulation”, “Aggression” and “Self-Harm” were 
included as additional outcome measures for use only in 
those who experience them. No adequate instrument for 
“Coping with Past Experiences of Trauma” was identified.
Table 1  List of all outcomes proposed for voting to working group
*No adequate instruments for ‘Coping with Past Experiences of Trauma’ were identified
Included outcomes Excluded outcomes
Emotional dysregulation Anxiety Mental well-being
Emotional distress Capacity for empathy Community participation
Suicide ideation and behaviour Depression/low mood Resilience
Self-harm Dissociation Self-compassion
Impulsivity Emptiness Self-esteem
Global functioning Guilt Self-efficacy
Interpersonal functioning Hopelessness Caregiver-youth relationship
Social functioning Obsessive rigidity Criminal activity
Sense of belonging Personality organization/pathology/temperament Family burden
Self-care Suicide Family mental health
Health-related quality of life Substance misuse Stigma
Identity disturbance Abuse of others (harming loved ones) Time to treatment
Aggression Pain Time to diagnosis
Severity of personality disorder Mortality Use of health services
Coping with Past Experiences of Trauma* Sleep Hospital admission
Self-awareness Cost of treatment and care
Sense of hope Use of other services
Satisfaction with services Patient-reported experience
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Case‑mix variables
Case-mix variables are included in the standard set in order 
to ensure the baseline comparability of treatment popula-
tions and intervention factors. ICHOM seeks to extract a 
minimum set of case-mix variables. Initially, a literature 
review and extraction from the registries and PD guide-
lines were performed to identify possible case-mix vari-
ables. Case-mix variables were compared against the other 
ICHOM mental health standard sets, and a harmonized ver-
sion consisting of demographic and intervention factors was 
confirmed by the working group (Table 4).
Data collection timepoints
Recommended timepoints for the collection of data should 
be looked at as the minimum requirement for measuring 
the defined outcomes. The outcome assessment timeline 
was proposed by the working group to best achieve a bal-
ance between the clinically relevant times when outcomes 
may be expected to change, and the pragmatic concerns in 
data collection. To harmonize across ICHOM mental health 
Standard Sets, a meeting between ICHOM mental health 
working group chairs was held to discuss the timepoints rec-
ommendation and suggestions were later voted on by each 
working group independently. The consensus reached was 
to recommend assessing outcomes prior to treatment as a 
baseline, every 3 months in continuous treatment until the 
discharge and then 6 months after discharge and annually 
thereafter when not in continuous treatment (Fig. 4).
Validation process
Seventy responses were received from mental health profes-
sionals in 17 countries. The survey was conducted online 
anonymously, and the respondents used a link to access and 
complete the survey. The survey was published on ICHOM’s 
website and shared within a number of newsletters, the mail-
ing lists of which were not disclosed to the authors of this 
manuscript. No further variables were collected from the 
respondents. All outcome domains included in the initial rec-
ommendation received high endorsement (85% confidence in 
overall domains) by the professionals in the open review panel. 
Sixty-three service users responded to the questions in the ser-
vice users validation survey and the outcomes ‘Aggression’, 
‘Identity Disturbance’ and ‘Emotional Dysregulation’ did not 
reach 70% endorsement. However, these outcomes, as well as 
the measures proposed to capture them, were highly endorsed 
by the professional open review panel. All three outcomes 
were discussed with the working group again, and the proposal 
was formed to include all the outcomes in the standard set. 
However, it was decided that ‘Emotional Dysregulation’ and 
‘Aggression’ would not be part of the core list of outcomes; the 
rationale being that not all people with PD experience aggres-
sion and emotional dysregulation.
Fig. 3  Recommended instrument package with assigned outcomes coverage and timing
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Discussion
As the case for measuring patient outcomes becomes 
increasingly accepted by clinicians and decision makers 
in health care, one of the challenges we are faced with 
is selecting which measures to use from among the vast 
array of different instruments that could be used. The 
ICHOM working group for PD responded to this chal-
lenge by selecting and defining a standardized minimum 
set of outcome measures that would be appropriate to use 
across different cultural and geographical settings [23]. 
The included outcomes represent those that matter most 
to people with PD. The measurement of these outcomes 
across different environments should help to build better 
communication between patients and providers. Bench-
marking of the results should motivate and empower pro-
viders to seek and share good practices and improve care 
and clinical protocols; payers would be able to clearly see 
the value of care and make informed decisions on strategic 
purchase strategies [24]. All the outcomes alongside case-
mix variables, timepoints for collection and questionnaires 
are freely available at the ICHOM website (https:// www. 
ichom. org/ stand ard- sets/).
ICHOM entered the mental health area in 2018. This area 
depends to an even higher degree on patient-reported out-
comes in comparison with some other clinical areas, where 
clinical readings can describe the outcomes relatively bet-
ter. Previous research [25] has shown that defining patient-
reported outcomes for PD, particularly BPD has many chal-
lenges. BPD has heterogeneous clinical features, meaning 
that patient-reported outcomes should include broad assess-
ment of psychopathology, but at the same time, measure 
stable as well as more dynamic aspects of the disorder. 
Social and occupational functioning are especially salient 
when assessing the outcomes of people with PD, because 
a number of studies have shown impaired functioning even 
when mental health improves [26]. Crawford et al. [27] 
conducted a Delphi study with service providers, services 
users and academic experts and similarly established that 
people with a wide range of PD felt that the most impor-
tant outcome measure that should be assessed was health-
related quality of life, followed by mental health and social 
functioning. Previous attempt [12] to identify core outcome 
measures in PD that capture quality of life, functioning and 
symptoms, highlighted that the number of outcomes for BPD 
is extensive. Above all, this attempt as well as the guidelines 
on the development of an agreed set of outcomes measures 
[26] were focused solely on BPD, while the ICHOM recom-
mended standard set is designed for all those with PD and 
related mental health conditions.
During the whole working process, lasting between 
October 2018 and June 2020, many scientists, clinicians 
and service user representatives were included in the for-
mulation of the standard set. All the members discussed 
the different steps of the work, from defining the scope to 
the preparation of the final manuscript. Due to the long 
period of preparing the final set, there was quite a high 
degree of fluctuation in the project team, as well as in the 
working group, but all involved expressed their valuable 
opinion and contributed effectively to the final outcome. 
The inclusion of the working group members was, how-
ever, based on their work recommendations and limited 
to people from 17 countries. In spite of extensive litera-
ture reviews and use of Delphi processes throughout the 
Fig. 4  Time guidance on the variables collected from service users and clinicians
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project, the results might have differed with a different 
group of participants from different cultural backgrounds.
The primary aim of the standard set is to reflect outcomes 
that are important to service users. Therefore, including their 
views and extensive inputs through the whole process is a 
strength of this work. There were six service user representa-
tives included in the working group and, in the end, 63 users 
(among them seven carers or parents) reviewed the final ver-
sion of the standard set, with 94% saying that all important 
outcomes are captured in the standard set and 96% saying 
that it would be useful having these outcomes collected. All 
of the service user representatives came from developed 
countries and most of them are from Europe.
The process of data collection via suggested question-
naires represents a significant time burden for service users 
as well as for clinicians. The participants had this in mind 
and tried to cover all the outcomes in the standard set with as 
few instruments as possible. Still, the outcomes in the final 
standard set are measured by eight instruments and the com-
plete collection of all outcomes lasts up to 30 min (including 
optional instruments). In many countries, the collection of 
PROMs is still not supported by information communica-
tion technology that would enable more efficient collection 
of data, less reluctance of the stakeholders and automated 
analysis and results. ICHOM is working on the information 
of data collection to support the users of the standard sets. 
In order to promote the use of the standard set in all inter-
national environments, the selected outcomes we chose are 
already translated into many languages. They are available 
in multiple formats, easily integrated into diverse data col-
lection tools, are computer adaptive and can be used free of 
charge. A very important issue in mental health standard sets 
is comorbidity of PDs with other mental health disorders, 
such as substance use disorders [28], attention-deficit hyper-
activity disorder [29] and schizophrenia [30]. Therefore, har-
monization of measures across the mental health standard 
set, as well as among other standard sets that include the 
same domains, is an important issue, which was taken into 
account in the process of the selection of measures.
Available evidence suggests that self-assessed measures 
made by people with PD have high test–retest reliability 
[31]. However, concerns have been raised about the reli-
ability of self-reported accounts of aggression and other 
externalizing behaviours [32]. ICHOM aims to estab-
lish person-centred outcomes. However, in recognition 
of the challenges of relying on self-report measures of 
aggression, a clinician-rated measure, the Modified Overt 
Aggression Scale, was selected to measure this outcome.
After undertaking a thorough systematic review, the 
working group was not able to identify an adequate outcome 
measure to capture the ‘Coping with Past Experiences of 
Trauma’ outcome. As the outcome is important to service 
users, the working group identified the lack of an appropriate 
instrument as a gap in the currently available outcome meas-
ures. Future research should be directed toward defining an 
appropriate instrument to measure this outcome. Various 
scales measuring similar constructs, such as ‘Posttraumatic 
growth’ have been looked at in the process and some of them 
overlap with ‘Coping with Past Experiences of Trauma’. 
As such, they might be helpful in defining an appropriate 
measure in the future. Additionally, discriminatory effects 
among different types of PD through the Standard Set of this 
ICHOM endeavour need to be studied further.
Furthermore, the standard set is not seen as fixed but 
should be updated regularly, following new developments 
in the clinical environment, as well as developments in the 
health measurement area. The standard set should be seen 
as a minimal set of outcomes and instruments for their 
measurement, and further outcomes and measures could 
be freely added to this set if needed.
Conclusions
The development of a minimal standard set of value-based 
service user-centred outcome measures in PD should lead 
to higher value of care, and better outcomes of care, for 
people with PD all across the world. Widespread use of 
these measures will lead to benchmarking and exchange 
of good practices, to greater inclusion of service users in 
care processes, and to better communication between clini-
cians and service users. It will also provide the payer with 
evidence that could serve as a basis for informed decision 
making on allocation of funds.
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